SARS-CoV-2 infections may be 10 times higher than reported cases, according to new data from a Centers for Disease Control and Prevention partnership with commercial laboratories to test de-identified clinical blood specimens for antibodies in Connecticut, South Florida, the New York City area, Missouri, Utah and western Washington state.

The seroprevalence survey includes people who had blood specimens tested for SARS-CoV-2 antibodies for reasons unrelated to COVID-19, such as for a routine or sick visit. CDC is working with state and local health departments to publish additional results from California, Louisiana, Minnesota, and Pennsylvania.

The survey aims to test about 1,800 samples from each of the 10 areas every 3 to 4 weeks to track changes in the percentage of people tested who have antibodies against SARS-CoV-2 in each area.

Related News Articles

Headline
A new AHA podcast explores how rural hospitals have found new ways to deliver care to patients with COVID-19. Brian Evans, CEO of Clarke County Hospital in…
Headline
Certain groups of workers showed significantly more absenteeism in March and April 2020, suggesting a link to COVID-19 exposure, according to a new study…
Headline
The Department of Health and Human Services today announced that it will distribute over $4 billion in additional funds from the Public Health and Social…
Perspective
Wear a mask. Wash your hands. Keep your distance. These are three simple actions we know that will stop the spread of COVID-19. The AHA, American Medical…
Headline
The Mount Sinai Health System will partner with Emergent BioSolutions and ImmunoTek Bio Centers on the development and evaluation of a COVID-19 hyperimmune…
Headline
Gilead Sciences yesterday said it is starting phase one clinical study of inhaled remdesivir for potential outpatient treatment of COVID-19. In a statement,…